Epidemiology and risk factors for human papillomavirus infection in a diverse sample of low-income young women

Journal of Clinical Virology

Volumn 46, Issue 2, 2009, Pages 107-111

  Shikary, Tasneem ^a   Bernstein, David I ^a,b   Jin, Yan ^a   Zimet, Gregory D ^c   Rosenthal, Susan L ^d   Kahn, Jessica A ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Cervical cancer; Epidemiology; Human papillomavirus; Sexually transmitted infection; Vaccination

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CANCER SCREENING; COLPOSCOPY; CONDOM; ETHNIC GROUP; FAMILY HISTORY; FEMALE; FEMALE GENITAL TRACT INFECTION; GENOTYPE; HEALTH INSURANCE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAID; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUESTIONNAIRE; RACE DIFFERENCE; RISK FACTOR; SAFE SEX; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; VACCINATION; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; CROSS-SECTIONAL STUDIES; ECONOMICS; FEMALE; HUMANS; LOGISTIC MODELS; MINORITY GROUPS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 69449085856     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2009.07.006     Document Type: Article

References (34)

1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
2. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 (2002) 244-265
3. Koulova A., Tsui J., Irwin K., Van Damme P., Biellik R., and Aguado M.T. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 26 (2008) 6529-6541
4. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4, 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
5. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278
6. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96 (2004) 604-615
7. Goldie S.J., O'Shea M., Campos N.G., Diaz M., Sweet S., and Kim S.Y. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 26 (2008) 4080-4093
8. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007) 1928-1943
9. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161-2170
10. Hildesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Bratti M.C., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298 (2007) 743-753
11. Centers for Disease Control Prevention. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices. Morb Mortal Wkly Rep 56 (2007) 1-24
12. Krieger N., Quesenberry Jr. C., Peng T., Horn-Ross P., Stewart S., Brown S., et al. Social class, race/ethnicity, and incidence of breast, cervix, colon, lung, and prostate cancer among Asian, Black, Hispanic, and White residents of the San Francisco Bay Area, 1988-92 (United States). Cancer Causes Control 10 (1999) 525-537
13. Freeman HP, Wingrove BK. Excess cervical cancer mortality: a marker for low access to health care in poor communities. Rockville, MD: National Cancer Institute, Center to Reduce Cancer Health Disparities May 2005. NIH Pub. No. 05-5282.
14. Kahn J.A., Lan D., and Kahn R.S. Sociodemographic factors associated with high-risk human papillomavirus infection. Obstet Gynecol 110 (2007) 87-95
15. Kahn J.A., Rosenthal S.L., Jin Y., Huang B., Namakydoust A., and Zimet G.D. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet Gynecol 111 (2008) 1103-1110
16. Kahn J.A., Slap G.B., Huang B., Rosenthal S.L., Wanchick A.M., Kollar L.M., et al. Comparison of adolescent and young adult self-collected and clinician-collected samples for human papillomavirus. Obstet Gynecol 103 (2004) 952-959
17. Gravitt P.E., Peyton C.L., Alessi T.Q., Wheeler C.M., Coutlee F., Hildesheim A., et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 38 (2000) 357-361
18. Coutlee F., Rouleau D., Ghattas G., Hankins C., Vezina S., Cote P., et al. Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test. J Clin Microbiol 45 (2007) 3821-3823
19. Tarkowski T.A., Koumans E.H., Sawyer M., Pierce A., Black C.M., Papp J.R., et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis 189 (2004) 46-50
20. Brown D.R., Shew M.L., Qadadri B., Neptune N., Vargas M., Tu W., et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 191 (2005) 182-192
21. Dunne E.F., Unger E.R., Sternberg M., McQuillan G., Swan D.C., Patel S.S., et al. Prevalence of HPV infection among females in the United States. JAMA 297 (2007) 813-819
22. Winer R.L., Feng Q., Hughes J.P., O'Reilly S., Kiviat N.B., and Koutsky L.A. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 197 (2008) 279-282
23. Wright Jr. T.C., Huh W.K., Monk B.J., Smith J.S., Ault K., and Herzog T.J. Age considerations when vaccinating against HPV. Gynecol Oncol 109 (2008) S40-S47
24. Chen C.A., Liu C.Y., Chou H.H., Chou C.Y., Ho C.M., Twu N.F., et al. The distribution and differential risks of human papillomavirus genotypes in cervical preinvasive lesions: a Taiwan Cooperative Oncologic Group Study. Int J Gynecol Cancer 16 (2006) 1801-1808
25. Castellsague Xea, Eds. HPV and Cervical Cancer in the World 2007 Report. Vaccine 2007;25 (Suppl. 3):C1-230.
26. Vet J.N., de Boer M.A., van den Akker B.E., Siregar B., Lisnawati, Budiningsih S., et al. Prevalence of human papillomavirus in Indonesia: a population-based study in three regions. Br J Cancer 99 (2008) 214-218
27. Ho C.M., Chien T.Y., Huang S.H., Lee B.H., and Chang S.F. Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecol Oncol 102 (2006) 54-60
28. Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Hansson B.G., et al. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer 97 (2007) 129-132
29. Burk R.D., Ho G.Y., Beardsley L., Lempa M., Peters M., and Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human Papillomavirus infection in young women. J Infect Dis 174 (1996) 679-689
30. Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., and Koutsky L.A. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157 (2003) 218-226
31. Shui I., Kennedy A., Wooten K., Schwartz B., and Gust D. Factors influencing African-American mothers' concerns about immunization safety: a summary of focus group findings. J Natl Med Assoc 97 (2005) 657-666
32. Shui I.M., Weintraub E.S., and Gust D.A. Parents concerned about vaccine safety: differences in race/ethnicity and attitudes. Am J Prev Med 31 (2006) 244-251
33. Newman P.A., Duan N., Roberts K.J., Seiden D., Rudy E.T., Swendeman D., et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr 41 (2006) 210-217
34. Moutsiakis D.L., and Chin P.N. Why blacks do not take part in HIV vaccine trials. J Natl Med Assoc 99 (2007) 254-257